The empagliflozin, dapagliflozin and canagliflozin market size has grown steadily in recent years. It will grow from $9.84 billion in 2025 to $10.07 billion in 2026 at a compound annual growth rate (CAGR) of 2.4%. The growth in the historic period can be attributed to type 2 diabetes prevalence, oral diabetes drug adoption, clinical guideline updates, cardiovascular risk awareness, lifestyle disease growth.
The empagliflozin, dapagliflozin and canagliflozin market size is expected to see steady growth in the next few years. It will grow to $11.08 billion in 2030 at a compound annual growth rate (CAGR) of 2.4%. The growth in the forecast period can be attributed to heart failure treatment expansion, renal protection evidence growth, diabetes combination therapy adoption, aging population, chronic disease management focus. Major trends in the forecast period include rising use of sglt-2 inhibitors in type 2 diabetes, expansion of cardiovascular benefit indications, increased preference for oral antidiabetic drugs, growth in combination diabetes therapies, strong focus on long-term glycemic control.
The rising prevalence of diabetes is expected to drive the growth of the empagliflozin, dapagliflozin, and canagliflozin market in the coming years. Diabetes is a chronic condition characterized by elevated blood sugar levels caused by insufficient insulin production or the body’s ineffective use of insulin. The increase in diabetes cases is attributed to factors such as sedentary lifestyles, poor dietary habits, genetic predisposition, urbanization, aging populations, limited access to healthcare, and rising global obesity rates. Empagliflozin, dapagliflozin, and canagliflozin help manage diabetes by lowering blood sugar levels through inhibition of the sodium-glucose co-transporter-2 (SGLT2) in the kidneys, promoting glucose excretion via urine. For example, in June 2024, according to the National Health Service (NHS), a UK-based government agency, the number of individuals under 40 with diabetes rose from 173,166 in 2022 to 216,440 in 2023. This notable increase highlights a concerning trend among younger populations. Therefore, the growing prevalence of diabetes is driving the empagliflozin, dapagliflozin, and canagliflozin market.
Major companies in the empagliflozin, dapagliflozin, and canagliflozin markets are focusing on developing innovative products, such as treatments for pediatric type-2 diabetes, to reach broader patient populations and expand their market presence. Pediatric type-2 diabetes treatment involves managing blood sugar levels through lifestyle interventions, medications, and occasionally insulin therapy, specifically tailored for children and adolescents. For instance, in June 2024, AstraZeneca, a UK-based pharmaceutical company, announced that the US Food and Drug Administration (FDA) had approved Farxiga (dapagliflozin) to improve glycemic control in pediatric patients aged 10 years and older with type-2 diabetes. This approval followed positive results from the T2NOW Phase III clinical trial, one of the largest pediatric type-2 diabetes studies to date, which demonstrated that Farxiga significantly reduced HbA1c levels compared to placebo. The safety profile in this patient group was consistent with that observed in adults with type-2 diabetes. This milestone highlights the limited availability of oral treatments for pediatric type-2 diabetes and underscores AstraZeneca’s commitment to advancing therapies across cardiovascular, renal, and metabolic diseases.
In March 2024, Nirma Limited, an India-based chemical company that manufactures, retails, and distributes commercial and industrial cleaning products, acquired a 75% stake in Glenmark Life Sciences for an undisclosed $682 million. Through this acquisition, Nirma Limited aims to strengthen its presence in the pharmaceutical sector, diversify its product portfolio, and leverage research and development capabilities for sustainable long-term growth. Glenmark Life Sciences, an India-based pharmaceutical company, manufactures APIs for empagliflozin, dapagliflozin, and canagliflozin, supporting the production of diabetes treatments.
Major companies operating in the empagliflozin, dapagliflozin and canagliflozin market are AstraZeneca PLC, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., MSN Laboratories Private Limited, Dr Reddy’s Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Cadila Healthcare Limited, Apotex Inc., Lupin Limited, Biocon Limited, Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Johnson & Johnson, Eli Lilly and Company, Glenmark Pharmaceuticals Ltd., Mitsubishi Tanabe Pharma Corporation, USV Ltd., Takeda Pharmaceutical Company Limited.
North America was the largest region in the empagliflozin, dapagliflozin and canagliflozin market in 2025. The regions covered in the empagliflozin, dapagliflozin and canagliflozin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the empagliflozin, dapagliflozin and canagliflozin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the empagliflozin, dapagliflozin and canagliflozin market by increasing costs of imported active pharmaceutical ingredients and finished drug formulations. Hospitals and pharmacies in developed regions are most affected due to reliance on imported medicines. These tariffs raise treatment costs by increasing drug procurement expenses for SGLT2 inhibitors, affecting affordability and long-term therapy adherence. However, they encourage local pharmaceutical manufacturing, supporting domestic API production and regional formulation of diabetes medications.
The empagliflozin, dapagliflozin and canagliflozin market research report is one of a series of new reports that provides empagliflozin, dapagliflozin and canagliflozin market statistics, including empagliflozin, dapagliflozin and canagliflozin industry global market size, regional shares, competitors with a empagliflozin, dapagliflozin and canagliflozin market share, detailed empagliflozin, dapagliflozin and canagliflozin market segments, market trends and opportunities, and any further data you may need to thrive in the empagliflozin, dapagliflozin and canagliflozin industry. This empagliflozin, dapagliflozin and canagliflozin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Empagliflozin, dapagliflozin, and canagliflozin are medications belonging to the class of sodium-glucose co-transporter-2 (SGLT-2) inhibitors, mainly used to treat type 2 diabetes mellitus. These drugs are administered orally and are part of a comprehensive diabetes management plan that also includes diet, exercise, and other medications as necessary.
The main types of these medications are empagliflozin, dapagliflozin, and canagliflozin. Empagliflozin is primarily used to lower blood glucose levels in adults with type 2 diabetes. It functions by helping the kidneys excrete glucose from the bloodstream via urine. These medications have various applications, including application I, application II, application III, and application IV, and are distributed through channels such as hospitals and pharmacies.
The empagliflozin, dapagliflozin and canagliflozin market consists of sales of jardiance, glyxambi, synjardy, farxiga, and invokamet. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The empagliflozin, dapagliflozin and canagliflozin market size is expected to see steady growth in the next few years. It will grow to $11.08 billion in 2030 at a compound annual growth rate (CAGR) of 2.4%. The growth in the forecast period can be attributed to heart failure treatment expansion, renal protection evidence growth, diabetes combination therapy adoption, aging population, chronic disease management focus. Major trends in the forecast period include rising use of sglt-2 inhibitors in type 2 diabetes, expansion of cardiovascular benefit indications, increased preference for oral antidiabetic drugs, growth in combination diabetes therapies, strong focus on long-term glycemic control.
The rising prevalence of diabetes is expected to drive the growth of the empagliflozin, dapagliflozin, and canagliflozin market in the coming years. Diabetes is a chronic condition characterized by elevated blood sugar levels caused by insufficient insulin production or the body’s ineffective use of insulin. The increase in diabetes cases is attributed to factors such as sedentary lifestyles, poor dietary habits, genetic predisposition, urbanization, aging populations, limited access to healthcare, and rising global obesity rates. Empagliflozin, dapagliflozin, and canagliflozin help manage diabetes by lowering blood sugar levels through inhibition of the sodium-glucose co-transporter-2 (SGLT2) in the kidneys, promoting glucose excretion via urine. For example, in June 2024, according to the National Health Service (NHS), a UK-based government agency, the number of individuals under 40 with diabetes rose from 173,166 in 2022 to 216,440 in 2023. This notable increase highlights a concerning trend among younger populations. Therefore, the growing prevalence of diabetes is driving the empagliflozin, dapagliflozin, and canagliflozin market.
Major companies in the empagliflozin, dapagliflozin, and canagliflozin markets are focusing on developing innovative products, such as treatments for pediatric type-2 diabetes, to reach broader patient populations and expand their market presence. Pediatric type-2 diabetes treatment involves managing blood sugar levels through lifestyle interventions, medications, and occasionally insulin therapy, specifically tailored for children and adolescents. For instance, in June 2024, AstraZeneca, a UK-based pharmaceutical company, announced that the US Food and Drug Administration (FDA) had approved Farxiga (dapagliflozin) to improve glycemic control in pediatric patients aged 10 years and older with type-2 diabetes. This approval followed positive results from the T2NOW Phase III clinical trial, one of the largest pediatric type-2 diabetes studies to date, which demonstrated that Farxiga significantly reduced HbA1c levels compared to placebo. The safety profile in this patient group was consistent with that observed in adults with type-2 diabetes. This milestone highlights the limited availability of oral treatments for pediatric type-2 diabetes and underscores AstraZeneca’s commitment to advancing therapies across cardiovascular, renal, and metabolic diseases.
In March 2024, Nirma Limited, an India-based chemical company that manufactures, retails, and distributes commercial and industrial cleaning products, acquired a 75% stake in Glenmark Life Sciences for an undisclosed $682 million. Through this acquisition, Nirma Limited aims to strengthen its presence in the pharmaceutical sector, diversify its product portfolio, and leverage research and development capabilities for sustainable long-term growth. Glenmark Life Sciences, an India-based pharmaceutical company, manufactures APIs for empagliflozin, dapagliflozin, and canagliflozin, supporting the production of diabetes treatments.
Major companies operating in the empagliflozin, dapagliflozin and canagliflozin market are AstraZeneca PLC, Boehringer Ingelheim GmbH, Teva Pharmaceutical Industries Ltd., MSN Laboratories Private Limited, Dr Reddy’s Laboratories Ltd., Aurobindo Pharma Limited, Cipla Limited, Cadila Healthcare Limited, Apotex Inc., Lupin Limited, Biocon Limited, Alkem Laboratories Ltd., Torrent Pharmaceuticals Ltd., Alembic Pharmaceuticals Ltd., Intas Pharmaceuticals Ltd., Johnson & Johnson, Eli Lilly and Company, Glenmark Pharmaceuticals Ltd., Mitsubishi Tanabe Pharma Corporation, USV Ltd., Takeda Pharmaceutical Company Limited.
North America was the largest region in the empagliflozin, dapagliflozin and canagliflozin market in 2025. The regions covered in the empagliflozin, dapagliflozin and canagliflozin market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the empagliflozin, dapagliflozin and canagliflozin market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are impacting the empagliflozin, dapagliflozin and canagliflozin market by increasing costs of imported active pharmaceutical ingredients and finished drug formulations. Hospitals and pharmacies in developed regions are most affected due to reliance on imported medicines. These tariffs raise treatment costs by increasing drug procurement expenses for SGLT2 inhibitors, affecting affordability and long-term therapy adherence. However, they encourage local pharmaceutical manufacturing, supporting domestic API production and regional formulation of diabetes medications.
The empagliflozin, dapagliflozin and canagliflozin market research report is one of a series of new reports that provides empagliflozin, dapagliflozin and canagliflozin market statistics, including empagliflozin, dapagliflozin and canagliflozin industry global market size, regional shares, competitors with a empagliflozin, dapagliflozin and canagliflozin market share, detailed empagliflozin, dapagliflozin and canagliflozin market segments, market trends and opportunities, and any further data you may need to thrive in the empagliflozin, dapagliflozin and canagliflozin industry. This empagliflozin, dapagliflozin and canagliflozin market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Empagliflozin, dapagliflozin, and canagliflozin are medications belonging to the class of sodium-glucose co-transporter-2 (SGLT-2) inhibitors, mainly used to treat type 2 diabetes mellitus. These drugs are administered orally and are part of a comprehensive diabetes management plan that also includes diet, exercise, and other medications as necessary.
The main types of these medications are empagliflozin, dapagliflozin, and canagliflozin. Empagliflozin is primarily used to lower blood glucose levels in adults with type 2 diabetes. It functions by helping the kidneys excrete glucose from the bloodstream via urine. These medications have various applications, including application I, application II, application III, and application IV, and are distributed through channels such as hospitals and pharmacies.
The empagliflozin, dapagliflozin and canagliflozin market consists of sales of jardiance, glyxambi, synjardy, farxiga, and invokamet. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Empagliflozin, Dapagliflozin and Canagliflozin Market Characteristics
3. Empagliflozin, Dapagliflozin and Canagliflozin Market Supply Chain Analysis
4. Global Empagliflozin, Dapagliflozin and Canagliflozin Market Trends and Strategies
5. Empagliflozin, Dapagliflozin and Canagliflozin Market Analysis of End Use Industries
7. Global Empagliflozin, Dapagliflozin and Canagliflozin Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Empagliflozin, Dapagliflozin and Canagliflozin Total Addressable Market (TAM) Analysis for the Market
9. Empagliflozin, Dapagliflozin and Canagliflozin Market Segmentation
10. Empagliflozin, Dapagliflozin and Canagliflozin Market Regional and Country Analysis
11. Asia-Pacific Empagliflozin, Dapagliflozin and Canagliflozin Market
12. China Empagliflozin, Dapagliflozin and Canagliflozin Market
13. India Empagliflozin, Dapagliflozin and Canagliflozin Market
14. Japan Empagliflozin, Dapagliflozin and Canagliflozin Market
15. Australia Empagliflozin, Dapagliflozin and Canagliflozin Market
16. Indonesia Empagliflozin, Dapagliflozin and Canagliflozin Market
17. South Korea Empagliflozin, Dapagliflozin and Canagliflozin Market
18. Taiwan Empagliflozin, Dapagliflozin and Canagliflozin Market
19. South East Asia Empagliflozin, Dapagliflozin and Canagliflozin Market
20. Western Europe Empagliflozin, Dapagliflozin and Canagliflozin Market
21. UK Empagliflozin, Dapagliflozin and Canagliflozin Market
22. Germany Empagliflozin, Dapagliflozin and Canagliflozin Market
23. France Empagliflozin, Dapagliflozin and Canagliflozin Market
24. Italy Empagliflozin, Dapagliflozin and Canagliflozin Market
25. Spain Empagliflozin, Dapagliflozin and Canagliflozin Market
26. Eastern Europe Empagliflozin, Dapagliflozin and Canagliflozin Market
27. Russia Empagliflozin, Dapagliflozin and Canagliflozin Market
28. North America Empagliflozin, Dapagliflozin and Canagliflozin Market
29. USA Empagliflozin, Dapagliflozin and Canagliflozin Market
30. Canada Empagliflozin, Dapagliflozin and Canagliflozin Market
31. South America Empagliflozin, Dapagliflozin and Canagliflozin Market
32. Brazil Empagliflozin, Dapagliflozin and Canagliflozin Market
33. Middle East Empagliflozin, Dapagliflozin and Canagliflozin Market
34. Africa Empagliflozin, Dapagliflozin and Canagliflozin Market
36. Empagliflozin, Dapagliflozin and Canagliflozin Market Competitive Landscape and Company Profiles
37. Empagliflozin, Dapagliflozin and Canagliflozin Market Other Major and Innovative Companies
40. Empagliflozin, Dapagliflozin and Canagliflozin Market High Potential Countries, Segments and Strategies
41. Appendix
Executive Summary
Empagliflozin, Dapagliflozin And Canagliflozin Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses empagliflozin, dapagliflozin and canagliflozin market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for empagliflozin, dapagliflozin and canagliflozin? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The empagliflozin, dapagliflozin and canagliflozin market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Type: Empagliflozin; Dapagliflozin; Canagliflozin2) By Application: Type 2 Diabetes Mellitus; Heart Failure; Chronic Kidney Disease; Other Applications
3) By Channel: Hospital; Pharmacy
Subsegments:
1) By Empagliflozin: Standard Empagliflozin; Extended-Release Empagliflozin; Combination Empagliflozin Formulations; Generic Empagliflozin2) By Dapagliflozin: Standard Dapagliflozin; Extended-Release Dapagliflozin; Combination Dapagliflozin Formulations; Generic Dapagliflozin
3) By Canagliflozin: Standard Canagliflozin; Extended-Release Canagliflozin; Combination Canagliflozin Formulations; Generic Canagliflozin
Companies Mentioned: AstraZeneca PLC; Boehringer Ingelheim GmbH; Teva Pharmaceutical Industries Ltd.; MSN Laboratories Private Limited; Dr Reddy’s Laboratories Ltd.; Aurobindo Pharma Limited; Cipla Limited; Cadila Healthcare Limited; Apotex Inc.; Lupin Limited; Biocon Limited; Alkem Laboratories Ltd.; Torrent Pharmaceuticals Ltd.; Alembic Pharmaceuticals Ltd.; Intas Pharmaceuticals Ltd.; Johnson & Johnson; Eli Lilly and Company; Glenmark Pharmaceuticals Ltd.; Mitsubishi Tanabe Pharma Corporation; USV Ltd.; Takeda Pharmaceutical Company Limited
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Empagliflozin, Dapagliflozin and Canagliflozin market report include:- AstraZeneca PLC
- Boehringer Ingelheim GmbH
- Teva Pharmaceutical Industries Ltd.
- MSN Laboratories Private Limited
- Dr Reddy’s Laboratories Ltd.
- Aurobindo Pharma Limited
- Cipla Limited
- Cadila Healthcare Limited
- Apotex Inc.
- Lupin Limited
- Biocon Limited
- Alkem Laboratories Ltd.
- Torrent Pharmaceuticals Ltd.
- Alembic Pharmaceuticals Ltd.
- Intas Pharmaceuticals Ltd.
- Johnson & Johnson
- Eli Lilly and Company
- Glenmark Pharmaceuticals Ltd.
- Mitsubishi Tanabe Pharma Corporation
- USV Ltd.
- Takeda Pharmaceutical Company Limited
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 10.07 Billion |
| Forecasted Market Value ( USD | $ 11.08 Billion |
| Compound Annual Growth Rate | 2.4% |
| Regions Covered | Global |
| No. of Companies Mentioned | 22 |
